You’re in the middle of a pulmonary block, cruising through a COPD/asthma set… and suddenly every answer choice is an inhaler you’ve “heard of,” but the stems all blur together. This is exactly where Step questions live: not “what is albuterol?” but why albuterol is right here—and why ipratropium, salmeterol, or fluticasone are wrong.
Tag: Pulmonary > Obstructive Lung Disease
The Vignette (Q-bank style)
A 68-year-old man with a 45–pack-year smoking history presents with progressive dyspnea and chronic cough. He has had two COPD exacerbations in the last year, one requiring hospitalization. Baseline spirometry shows FEV1/FVC = 0.55. He is currently using albuterol as needed and tiotropium daily. Today he is back to baseline but asks what else can reduce his future flare-ups. Labs show blood eosinophils 350 cells/µL.
Which medication is the best next step to reduce COPD exacerbations?
A. Inhaled fluticasone
B. Inhaled albuterol
C. Inhaled salmeterol
D. Oral montelukast
E. IV omalizumab
Stepwise Approach: What are they really asking?
They’re asking: Which inhaler class reduces COPD exacerbations in a patient with frequent exacerbations—and they handed you a huge clue: eosinophilia.
Key data:
- COPD with frequent exacerbations (≥2/year or ≥1 hospitalization)
- Already on:
- SABA (albuterol PRN) for rescue
- LAMA (tiotropium) maintenance bronchodilation
- High blood eosinophils (often predicts better response to inhaled corticosteroids in COPD)
Correct Answer: A. Inhaled fluticasone (ICS)
Why it’s correct
In COPD, inhaled corticosteroids (ICS) are not for every patient—but they’re high-yield for:
- Frequent exacerbators, especially with elevated eosinophils (commonly ≥300 cells/µL)
- Patients with asthma-COPD overlap features
Mechanism (board-level):
- ICS decreases airway inflammation, which translates into fewer exacerbations in the right phenotype (eosinophilic inflammation tends to be more steroid-responsive).
How it’s used clinically:
- Often added as part of:
- LABA/ICS (e.g., salmeterol/fluticasone)
- Triple therapy: LAMA + LABA + ICS in frequent exacerbators
USMLE pearl:
Bronchodilators improve symptoms/FEV1, but ICS is the classic add-on to reduce exacerbations in COPD patients with recurrent exacerbations + eosinophilia.
Major adverse effect to remember
- Increased pneumonia risk in COPD (especially older patients, severe disease)
- Also: oral candidiasis, dysphonia (hoarseness)
Why Each Distractor is Wrong (and when it would be right)
B. Inhaled albuterol (SABA)
Why it’s wrong here:
Albuterol is a rescue inhaler for acute symptoms. It does not meaningfully reduce long-term exacerbation frequency as a step-up preventive strategy.
When it’s right:
- Acute bronchospasm relief in asthma/COPD
- Pre-exercise bronchospasm prophylaxis in asthma
High-yield mechanism: agonist → ↑cAMP in bronchial smooth muscle → bronchodilation.
Key adverse effects: tremor, tachycardia, hypokalemia (shift into cells), hyperglycemia.
C. Inhaled salmeterol (LABA)
Why it’s wrong here:
A LABA is excellent maintenance therapy, but the patient is specifically a frequent exacerbator already on LAMA with eosinophilia, where the big “next step” tested is often adding ICS (commonly via LABA/ICS or triple therapy). LABA alone may improve symptoms but is less directly tied (in test logic) to the eosinophil clue.
When it’s right:
- COPD maintenance (often LABA + LAMA)
- Asthma maintenance only with ICS (never LABA monotherapy in asthma)
USMLE warning:
LABA monotherapy in asthma increases asthma-related deaths → must combine with ICS.
Adverse effects: similar to SABA (tachycardia, tremor).
D. Oral montelukast (leukotriene receptor antagonist)
Why it’s wrong here:
Montelukast is an asthma medication (and allergic rhinitis). It’s not a standard COPD exacerbation-reduction drug.
When it’s right:
- Asthma with:
- Aspirin-exacerbated respiratory disease (AERD)
- Exercise-induced bronchoconstriction (adjunct)
- Allergic rhinitis
High-yield adverse effect:
- Neuropsychiatric symptoms (boxed warning): agitation, depression, suicidal ideation
E. IV omalizumab (anti-IgE)
Why it’s wrong here:
Omalizumab is for moderate-to-severe allergic asthma (and chronic idiopathic urticaria), not typical COPD.
When it’s right:
- Asthma with:
- Elevated IgE
- Positive allergen sensitization
- Poor control despite ICS/LABA
High-yield adverse effect: anaphylaxis (rare but tested).
The High-Yield Inhaler Map (Step 1 → Step 2 bridge)
Quick “what does what” table
| Class | Example | Main use | Primary benefit | Classic adverse effects |
|---|---|---|---|---|
| SABA | Albuterol | Asthma/COPD rescue | Rapid bronchodilation | Tremor, tachycardia, hypokalemia |
| LABA | Salmeterol, formoterol | Maintenance | Long bronchodilation | Same as SABA; never alone in asthma |
| SAMA | Ipratropium | COPD rescue/adjunct | Bronchodilation | Dry mouth, urinary retention |
| LAMA | Tiotropium | COPD maintenance | ↓ symptoms, ↓ exacerbations | Anticholinergic effects |
| ICS | Fluticasone, budesonide | Asthma cornerstone; COPD selected pts | ↓ airway inflammation, ↓ exacerbations | Oral thrush, dysphonia, pneumonia risk in COPD |
| PDE-4 inhibitor | Roflumilast | Severe COPD + chronic bronchitis | ↓ exacerbations | Weight loss, insomnia, depression |
| Anti-IgE | Omalizumab | Allergic asthma | ↓ exacerbations | Anaphylaxis |
| Anti–IL-5 | Mepolizumab, reslizumab | Eosinophilic asthma | ↓ exacerbations | Hypersensitivity |
| Anti–IL-4/13 | Dupilumab | Eosinophilic/type 2 asthma | ↓ exacerbations | Conjunctivitis, eosinophilia |
COPD vs Asthma: The “Inhaler Logic” the NBME Loves
COPD (big picture)
- First-line = bronchodilators (LAMA/LABA)
- Add ICS when:
- Frequent exacerbations AND/or
- High eosinophils (steroid-responsive phenotype) AND/or
- Asthma overlap
Clinical anchor:
If the stem is shouting “COPD exacerbation prevention” + eosinophils → think ICS add-on (often as part of triple therapy).
Asthma (big picture)
- ICS is foundational controller therapy
- SABA for rescue
- LABA only with ICS
- Biologics (omalizumab, anti–IL-5, dupilumab) for severe asthma phenotypes
Extra High-Yield “Answer Choice Traps” to recognize
-
“Short-acting anticholinergic” vs “short-acting beta agonist” in COPD exacerbations:
- In acute COPD exacerbation: SABA ± SAMA are both used.
- For maintenance: LAMA/LABA.
-
ICS in COPD is not automatic.
If the patient has recurrent pneumonias or low eosinophils and minimal exacerbations, ICS may be low yield or harmful. -
Spirometry clue for obstruction:
- Obstructive disease: low FEV1/FVC
- COPD hallmark: less reversible than asthma after bronchodilator
Takeaway: How to win inhaler questions fast
- Identify the disease (COPD vs asthma) and the goal (rescue vs maintenance vs exacerbation prevention).
- Match the clue:
- Eosinophils/high exacerbation burden → ICS helps prevent exacerbations (COPD selected patients; asthma broadly).
- Use the distractors:
- SABA = rescue
- LABA = maintenance bronchodilation (but asthma needs ICS)
- LAMA = best COPD maintenance/exacerbation reduction backbone
- Montelukast/omalizumab = asthma phenotypes, not standard COPD